Molfino, A.; Imbimbo, G.; Pisegna, S.; Scagnoli, S.; Alabiso, C.; Ardovino, M.; Gallicchio, C.; Rizzo, V.; Botticelli, A.
Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan. Cancers 2025, 17, 3063.
https://doi.org/10.3390/cancers17183063
AMA Style
Molfino A, Imbimbo G, Pisegna S, Scagnoli S, Alabiso C, Ardovino M, Gallicchio C, Rizzo V, Botticelli A.
Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan. Cancers. 2025; 17(18):3063.
https://doi.org/10.3390/cancers17183063
Chicago/Turabian Style
Molfino, Alessio, Giovanni Imbimbo, Simona Pisegna, Simone Scagnoli, Claudia Alabiso, Massimiliano Ardovino, Carmen Gallicchio, Veronica Rizzo, and Andrea Botticelli.
2025. "Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan" Cancers 17, no. 18: 3063.
https://doi.org/10.3390/cancers17183063
APA Style
Molfino, A., Imbimbo, G., Pisegna, S., Scagnoli, S., Alabiso, C., Ardovino, M., Gallicchio, C., Rizzo, V., & Botticelli, A.
(2025). Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan. Cancers, 17(18), 3063.
https://doi.org/10.3390/cancers17183063
